Navigation Links
Cordex Receives Special Protocol Assessment Approval from FDA for ATPace(TM)
Date:6/2/2009

LA JOLLA, Calif., June 2 /PRNewswire-FirstCall/ -- Cordex Pharma, Inc. (OTC Bulletin Board: CDXP) announced today that the U.S. Food and Drug Administration (FDA) has approved the design of pivotal, Phase 2b/3 clinical trials evaluating its lead product ATPace(TM) as an antiarrhytmic drug for the acute treatment of patients with paroxysmal supraventricular tachycardia (PSVT) under the Special Protocol Assessment (SPA) process.

ATPace(TM) is a novel stable liquid formulation of adenosine 5'-triphosphate (ATP). It is being developed as a therapeutic and diagnostic drug for the management of patients with cardiac arrhythmias. ATP has been used in Europe for more than five decades as the drug of choice for the acute termination of PSVT. During this extended period of time, formulations of ATP have manifested an excellent safety and efficacy profile.

Cordex intends to initiate prospective, double-blind, placebo-controlled and randomized clinical trials with its lead product ATPace(TM) in approximately 200 patients aimed at demonstrating clinical safety and efficacy sufficient to support a New Drug Application filing of ATPace(TM) for the treatment of PSVT in emergency room patients.

"We are very pleased with the FDA's decision; we believe that data to be obtained in the proposed trials would constitute sufficient evidence to support the marketing approval of ATPace(TM) for the proposed indication," commented Amir Pelleg, Ph.D., Cordex's President and CSO. "Due to its unique mechanism of action in the heart, which involves a central vagal reflex and adenosine, the product of its rapid degradation, ATPace(TM) has the potential to be an important advance in the treatment of patients with PSVT," he added.

About PSVT

PSVT is an episodic, rapid, regular heart rate originating in the atria. The heart rate in PSVT can range from 150 to 250 beats per minute. There are approximately 57
'/>"/>

SOURCE Cordex Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Cordex Pharma to Collaborate with BG Medicine in a Clinical Study of Heart Failure Biomarkers
2. Cordex Pharma Files ATPace Formulation Patent
3. Cordex Pharma Submits to the FDA an Amended Special Protocol Assessment for ATPace
4. Cordex Pharma Sets Fourth Quarter 2008 Program Update Call
5. Respected Surgeon Receives Emmy Nomination
6. Edward Diehl Receives Outstanding Achievement Award From the American College of Addiction Treatment Administrators (ACATA)
7. LA BioMed researcher receives clinical teaching award
8. SAFC Pharmas St. Louis HPAPI Conjugates Facility Receives SafeBridge Certification
9. ALIMTA(R) (pemetrexed for injection) Receives Positive Opinion From CHMP as Maintenance Therapy for Nonsquamous Non-Small Cell Lung Cancer
10. Bausch & Lomb Receives FDA Approval of Besivance(TM), New Topical Ophthalmic Antibacterial for the Treatment of Bacterial Conjunctivitis (Pink Eye)
11. Family Health International Receives $100,000 Grand Challenges Explorations Grant for Innovative Global Health Research Project Led by David Sokal, M.D.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... McLean, Va. (PRWEB) September 16, 2014 ... use through predictive analytics and targeted clinical programs, ... The announced changes support the Company’s drive to ... analytics and targeted clinical programs. On September 2, ... parent company, Millennium Health, announced that RxAnte founder ...
(Date:9/16/2014)... News) -- Illegal drug use among teens in the United ... report. Encouragingly, the new study also found that ... among young people between the ages of 12 and 17 ... of 70,000 people aged 12 and older across the United ... abuse problems among this age group also dropped from 8.9 ...
(Date:9/16/2014)... YORK, NY (September 16, 2014) The Columbia ... the 2014 Higher Education Excellence in Diversity (HEED) ... and largest diversity-focused publication in higher education. As ... honor recognizing U.S. colleges and universities that demonstrate ... be featured along with 82 other recipients in ...
(Date:9/16/2014)... September 15, 2014A prospective study that compared patient-reported ... with bone metastases demonstrates that single fraction radiation ... fraction radiation therapy (MFRT) when pain, function and ... presented today at the American Society for Radiation ... indicates that improvements in patients, pain, function and ...
(Date:9/16/2014)... September 16, 2014 Fresh shiitake ... iron and potassium. They are second-most consumed mushroom ... and their healing and health properties. , In ... Shiitakes can stimulate and strengthen the immune system ... contain polycharrides, including beta glucans . These ...
Breaking Medicine News(10 mins):Health News:Millennium Health’s RxAnte Subsidiary Announces Leadership Promotions 2Health News:Millennium Health’s RxAnte Subsidiary Announces Leadership Promotions 3Health News:Fewer U.S. Teens Using Illegal Drugs and Alcohol, Report Finds 2Health News:Columbia University College of Dental Medicine receives diversity award 2Health News:Columbia University College of Dental Medicine receives diversity award 3Health News:Columbia University College of Dental Medicine receives diversity award 4Health News:Single fraction RT as effective as multiple fraction RT for bone metastases 2Health News:Single fraction RT as effective as multiple fraction RT for bone metastases 3Health News:Single fraction RT as effective as multiple fraction RT for bone metastases 4Health News:As Fall Schedules Settle In, Block Stress-Related Illness with Your Own Shiitake Mushroom Log Kit from Lost Creek Mushroom Farm 2Health News:As Fall Schedules Settle In, Block Stress-Related Illness with Your Own Shiitake Mushroom Log Kit from Lost Creek Mushroom Farm 3
... ULURU Inc. (NYSE AMEX: ULU ) ... 31, 2009. The Company reported a net loss of $3.1 ... $1.8 million, or $0.03 per share, for the same period last ... cash equivalents of $5.1 million, compared with $7.6 million at December ...
... Calif., May 15 Thoratec Corporation (Nasdaq: ... support therapies to save, support and restore failing hearts, ... former chief operating officer of Boston Scientific, to its ... shareholders at the company,s annual shareholders, meeting on May ...
... Richard Boland, M.D., chief of gastroenterology at Baylor ... vice president of the American Gastroenterological Association (AGA) Institute, ... 2011. The oldest medical specialty society in the United ... and practice of gastroenterology. AGA membership includes 16,500 physicians ...
... & PARIS, FRANCE The International Union for ... Public Health Education (SOPHE) are pleased to release today ... standards and quality assurance systems of global capacity in ... Health Education & Behavior (Vol. 36, No. 3, ...
... of Ultrasound in Medicine is pleased to announce the ... All operators of ultrasound systems with an output display ... consists of 3 parts: Bioeffects and Biophysics, Prudent Use, ... the information from this 64 page publication, users can ...
... Group, Inc. (Nasdaq: NYER ) reported results for ... for third quarter of fiscal 2009 increased $1.3 million or ... the comparable quarter in the prior year. The increase ... new pharmacies over the past 12 months. Revenues slightly ...
Cached Medicine News:Health News:ULURU Inc. Reports First Quarter 2009 Financial Results 2Health News:ULURU Inc. Reports First Quarter 2009 Financial Results 3Health News:ULURU Inc. Reports First Quarter 2009 Financial Results 4Health News:ULURU Inc. Reports First Quarter 2009 Financial Results 5Health News:ULURU Inc. Reports First Quarter 2009 Financial Results 6Health News:Thoratec Announces Appointment of Paul LaViolette to Board of Directors 2Health News:Thoratec Announces Appointment of Paul LaViolette to Board of Directors 3Health News:Dallas Gastroenterologist Named Vice President of Prestigious National Organization 2Health News:Special journal issues released on global health promotion and health education 2Health News:AIUM releases second edition of 'Medical Ultrasound Safety' 2Health News:Nyer Medical Group, Inc. Reports Revenues of $18.6 Million for the Quarter Ended March 31, 2009 2Health News:Nyer Medical Group, Inc. Reports Revenues of $18.6 Million for the Quarter Ended March 31, 2009 3Health News:Nyer Medical Group, Inc. Reports Revenues of $18.6 Million for the Quarter Ended March 31, 2009 4Health News:Nyer Medical Group, Inc. Reports Revenues of $18.6 Million for the Quarter Ended March 31, 2009 5
(Date:9/16/2014)... , Sept. 16, 2014 Based ... closure market, Frost & Sullivan recognises Incisive Surgical ... for Customer Value Leadership. Incisive Surgical,s uniquely-designed, innovative ... technology that eliminates the need for patients to ... and staple removal  that may result in increased ...
(Date:9/16/2014)... , Sept. 16, 2014 CorMedix ... focused on developing and commercializing therapeutic products for ... infectious diseases, announces the amendment and restatement of ... preferred stock and related warrants, as well as ... stock and warrant financing, to remove anti-dilution, price ...
(Date:9/16/2014)... , Sept. 16, 2014  DNAtrix, Inc., experts ... first patient was treated with the company,s lead ... interferon in a randomized, multicenter, open-label Phase Ib ... "DNAtrix, in collaboration with leading neurosurgeons and neuro-oncologists ... initiation of our randomized Phase Ib study of ...
Breaking Medicine Technology:Frost & Sullivan Commends Incisive Surgical for Delivering Superior Customer Value through its Patient-Centric, Cost-Effective INSORB Absorbable Stapler 2Frost & Sullivan Commends Incisive Surgical for Delivering Superior Customer Value through its Patient-Centric, Cost-Effective INSORB Absorbable Stapler 3Frost & Sullivan Commends Incisive Surgical for Delivering Superior Customer Value through its Patient-Centric, Cost-Effective INSORB Absorbable Stapler 4Frost & Sullivan Commends Incisive Surgical for Delivering Superior Customer Value through its Patient-Centric, Cost-Effective INSORB Absorbable Stapler 5CorMedix Amends and Restates Outstanding Securities to Remove Provisions Causing Derivative Liability Classification 2CorMedix Amends and Restates Outstanding Securities to Remove Provisions Causing Derivative Liability Classification 3DNAtrix Announces Treatment Of First Patient With DNX-2401 In Recurrent Glioblastoma Trial 2
... HARTLAND, Wis., Aug. 30, 2011 H&P Industries, Inc., ... hiring of Eamonn Vize to fill the Chief Operating ... 20 years of experience in the Pharmaceutical and Biotechnology ... provide his knowledge of Pharmaceutical Operations and Validations to ...
... , a leading supplier of embedded technologies, products, and ... embedded computers to a medical original equipment ... of the six-month contract is about 1.5M USD. ... will allow the customer to meet market demand and ...
Cached Medicine Technology:Eurotech Awarded 1.5M USD Contract to Supply Embedded Computers for Medical Application 2
...
...
Rhoton Curettes, titanium, length 191 mm, straight....
Sundt Slim-Line Temporary Vessel Clips used for temporary vascular occlusion during intracranial surgical procedures. Non-magnetic, MP35N, MRI compatible, gold color. Bayonet....
Medicine Products: